•  
  •  
  •  
  •  

2026-07-10 21:55:31

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Innovision Ltd receives LoA worth Rs. 9.23 crores
  • Actian Expands Data Management Portfolio with Jaspersoft Embedded Analytics and Reporting
  • Jayant Infratech Ltd receives order worth Rs. 13.31 crores
  • Uno Minda announces Greenfield Plant in Chhatrapati Sambhaiinagar with Rs. 320 Crore Investment
  • Siyaram Recycling Industries Ltd secures order worth Rs. 36.95 lakhs

Keywords Selected:  AlembicPharmaceuticals

Stock Report

  • Alembic Pharmaceuticals Limited receives USFDA Final Approval for Dapsone Gel, 5%
  • Alembic Pharmaceuticals Limited announces USFDA Tentative Approval for Binimetinib Tablets, 45 mg
  • Alembic Pharmaceuticals Limited announces USFDA Final Approval for Tretinoin Cream USP, 0.05%
  • Alembic Pharmaceuticals Ltd announces USFDA Tentative Approval for Larotrectinib Capsules, 25 mg and 100 mg
  • Alembic Pharmaceuticals Ltd announces USFDA Final Approval for Haloperidol Tablets, USP, 1 mg, 2 mg, 5 mg, 10 mg, and 20 mg
  • Alembic Pharmaceuticals Appoints Mr. Ramesh Juneja as Executive Vice President - Human Health (Sales and Marketing), India Business
  • Alembic Pharmaceuticals Ltd announces USFDA Final Approval for Levothyroxine Sodium Tablets USP
  • Alembic Pharmaceuticals Limited announces USFDA Final Approval for Fingolimod Capsules, 0.5 mg
  • Alembic Pharmaceuticals Ltd announces USFDA Final Approval for Methotrexate Injection USP
  • Alembic Pharmaceuticals Limited announces USFDA Final Approval for Dapagliflozin Tablets, 5 mg and 10 mg
  • Alembic Pharmaceuticals Ltd announces USFDA Final Approval for Paroxetine Extended-Release Tablets USP, 12.5 mg
  • Alembic Pharmaceuticals Achieves First US Prescription Sale of PivyaĀ® Antibiotic
  • Alembic Pharmaceuticals Limited announces USFDA Final Approval for Lamotrigine Orally Disintegrating Tablets USP, 25 mg, 50 mg, 100 mg and 200 mg
  • Alembic Pharmaceuticals Limited announces USFDA Final Approval for Efinaconazole Topical Solution, 10%
  • Alembic Pharmaceuticals Ltd receives 2 observations for Karakhadi Injectable Facility
  • Alembic Pharmaceuticals gets USFDA nod for generic Parkinson's disease treatment tablets
  • Alembic Pharmaceuticals Limited announces USFDA Final Approval for Travoprost Ophthalmic Solution USP, 0.004%
  • Alembic Pharmaceuticals Ltd announces USFDA Final Approval for Loteprednol Etabonate and Tobramycin Ophthalmic Suspension, 0.5%/0.3%
  • Alembic Pharmaceuticals Ltd announces USFDA Final Approval for Diltiazem Hydrochloride Tablets USP, 30 mg, 60 mg, 90 mg, and 120 mg
  • Alembic Pharmaceuticals Ltd announces USFDA Final Approval Dexlansoprazole Delayed Release Capsules, 30 mg and 60 mg
  • Alembic Pharmaceuticals Ltd announces USFDA Final Approval for Sumatriptan Injection USP, 4 mg/0.5 mL and 6 mg/0.5 mL, Single-Dose Autoinjector System
  • Alembic Pharmaceuticals Ltd announces USFDA Final Approval for Dasatinib Tablets, 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg
  • Alembic Pharmaceuticals Ltd Q2FY26 consolidated PAT rises to Rs. 183.71 crores
  • Alembic Pharmaceuticals Ltd announces USFDA Final Approval for Triamcinolone Acetonide Injectable Suspension USP, 40 mg/mL

Latest Post

  • Innovision Ltd receives LoA worth Rs. 9.23 crores
  • Actian Expands Data Management Portfolio with Jaspersoft Embedded Analytics and Reporting
  • Jayant Infratech Ltd receives order worth Rs. 13.31 crores
  • Uno Minda announces Greenfield Plant in Chhatrapati Sambhaiinagar with Rs. 320 Crore Investment
  • Siyaram Recycling Industries Ltd secures order worth Rs. 36.95 lakhs


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2025